Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Roivant sciences - The Untold Story

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

MarketBeat

This Red-Hot Biopharma Stock Could Fizzle Out Soon

Roivant Sciences (ROIV) shows strong technical momentum and is trading at new all-time highs. Shares are up 52% over the past year and 20% in the last month. ROIV has a 100% “Buy” opinion from Barchart and a Trend Seeker “Buy” signal. Despite the price gains, Roivant lacks consistent revenue...

Barchart

Quick Facts About Vivek Ramaswamy: Net Worth, How He Met His Wife, Ohio Governor Run, and More

Vivek Ramaswamy, a biotech entrepreneur and former Republican presidential candidate, has announced his bid for Ohio governor as he secures Donald Trump's endorsement.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio?

While Roivant Sciences (ROIV) has been seeing stable revenue growth, its bottom line is in the red. So, will it be worth owning ROIV now? Let’s discuss some of its key financial metrics to gauge its prospects.

StockNews.com

Vivek Ramaswamy: the ‘millennial tech bro’ running for president

The multimillionaire former biotech executive Vivek Ramaswamy took centre stage at the first Republican debate last week as he bids to win his party’s 2024 presidential nomination.

The Week

Who is Vivek Ramaswamy? Trump nominates Ramaswamy and Elon Musk to lead new efficiency department

Vivek Ramaswamy is the son of an immigrant family from Kerala

Evening Standard

Analyst Ratings for Roivant Sciences

Within the last quarter, Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2022

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.